Aminoglycoside: Amikacin (AMK), Gentamicin (GEN), Synergism Gentamicin (SGEN), Synergism Streptomycin (SSTP), Tobramycin (TOB); Cephalosporins: Cefepime (FEP), Cefoxitin (FOX), Ceftaroline (CPT), Ceftazidime (CAZ), Ceftazidime + Avibactam (CZA), Ceftriaxone (CRO), Cefuroxime (CXM), Cefazolin (CZ); Quinolones: Ciprofloxacin (CIP), Norfloxacin (NX), Levofloxacin (LVX); Penicillin: Amoxicillin/Clavulanic acid (AMC), Ampicillin (AMP), Ampicillin/Sulbactam (SAM), Oxacillin (OXA), Penicillin (PEN), Piperacillin/Tazobactam (TZP); Carbapenems: Ertapenem (ETP), Imipenem (IPM), Meropenem (MEM); Glycopeptides: Teicoplanin (TEC), Vancomycin (VAN): Macrolide: Erythromycin (ERY), Rifampicin (RIP): Lincosamides: Clindamycin (CLI); Oxazolidinone: Linezolid (LZD); Tetracycline: Tetracycline (TET), Minocycline (MIN); Sulfonamides: Sulfamethoxazole/Trimethoprim (STX); Nitroimidazoles: Nitrofurantoin (NIT); Amphenicol: Chloramphenicol (C); Phosphonate: Fosfomycin (FOS); Glycylcyclines: Tigecycline (TGC); Polypeptide: Colistin (CL); Lipopeptides: Daptomycin (DAP).
The resistance profile was classified as resistant (R), and susceptible (S). Any isolate with resistance to three or more classes of antimicrobial agents was classified as multidrug-resistant (MDR) according to the definition proposed by Magiorakos et al. (2012) (link). Some of the clinical isolates were retrieved at the moment of hospitalization for epidemiological active surveillance and infection control. A total of 256 isolates were included in the study and 196 had the antimicrobial susceptibility test performed (
Data for new COVID-19 cases for each month were obtained from the Brazilian Ministry of Health (MS) and the State Health Department of Rio de Janeiro, compiled by Cota (2020) .
The prevalence of bacteria species in pediatric, neonatal-ICU, and gynecology/obstetrics wards during the pandemic period was evaluated. In order to compare these three wards with other hospital wards, a total of 2,551 bacteria isolates were recovered from the HICC-HUAP.